1LJUNGMAN P, GRIFFITHS P, PAYA C. Defini- tions of cytomegalovirus infection and disease in transplant recipients[J]. Clin Infect Dis, 2002, 34: 1094--1097.
2KOTTON C N,KUMAR D,CALIENDO A M,et al. International consensus guidelines on the manage- ment of cytomegalovirus in solid organ transplanta- tion[J]. Transplantation, 2010,89 : 779-- 795.
3FISHMAN J A, EMERY V, FREEMAN R, et al. Cytomegalovirus in transplantation - challenging the status quo[J]. Clin Transplant, 2007,21 : 149 -- 158.
4WEIKERT B C, BLUMBERG E A. Viral infection after renal transplantalion: surveillance and manage- ment[J].Clin J Am Soc Nephrol,2008,3 Suppl 2: $76--86.
5CORDERO E, CASASOI.A C, ECARMA R, et al. Cytomegalovirus disease in kidney transplant recipi- ents:incidence, clinical profile, and risk factors [J].Transplant Proc, 2012,44 : 694-- 700.
7AOBOTT K C HYPOI.ITE I O, VIOI.A R, et al. Hospitalizations for cytomegalovirus disease after re- nal transplantation in the United States[J]. Ann Epi- demiol, 2002,12 : 402 -- 409.
8DE KEYZER K, VAN LAECKE S, PEETERS P, et al. Human cytomegalovirus and kidney transplanta- tion:a clinician's update[J]. Am J Kidney Dis,2011, 58:118--126.
9REISCHIG T. Cytomegalovirus-associated renal al- lograft rejection: new challenges for antiviral preven- tive strategies[J]. Expert Rev Anti Infect Ther, 2010,8:903--910.
10TOI.KOFF-RUBIN N E, FISHMAN J A, RUBIN R H. The bidirectional relationship between cytomega- lovirus and allograft injury[J].Transplant Proc, 2001, 33: 1773--1775.
2Eid AJ,Razonable RR.Cytomegalovirus disease in solid organ transplant recipients:advances lead to new challenges and opportunities[J].Curr Opin Infect Dis,2007,12(6):610-617.
3Florencia P,Robert HR.Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients[J].Curr Opin Infect Dis,2004,17(4):357-361.
4Lischka P,Zimmermann H,et al.Antiviral strategies to combat cytomegalovirus infections in transplant recipients[J].Curr Opin Pharmacol,2008,8(5):541-548.
5Lopau K,Greser A,Wanner C.Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation[J].Clin Transplant,2007,21(1):80-85.
6Small LN,Lau J,Snydman DR.Preventing post-organ transplantation cytomegalovirus disease with ganciclovir:a meta-analysis comparing prophylactic and preemptive therapies[J].Clin Infect Dis,2006,43(7):869-880.
7Khoury JA,Storch GA,Bohl DL,et al.Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients[J].Am J Transplant,2006,6(9):2 134-2 143.
8Asberg A,Humar A,Rollag H,et al.Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients[J].Am J Transplant,2007,7(9):2 106-2 113.
9Husain S,Pietrangeli CE,Zeevi A.Delayed onset CMV disease in solid organ transplant recipients[J].Transpl Immunol,2009,21(1):1-9.
